Focused on genetic medicines for rare diseases, the company develops RNA- and gene-therapy treatments targeting conditions such as Duchenne muscular dystrophy. Its pipeline and recently approved gene therapies have placed it at the center of investor attention around pricing, regulatory decisions, a...
No congressional trades have been disclosed for Sarepta Sponsored ADR (TESX) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.